Clinical Trial: Mifepristone for Patients With Endometrial Cancer and LGESS

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional



Official Title: Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)

Brief Summary:

Primary Objectives:

  1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS).
  2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient population.
  3. To evaluate at a tissue level the effect of Mifepristone on estrogen and progesterone receptors post treatment and to evaluate other markers that may reflect effects of Mifepristone on cancer cell growth.
  4. To evaluate the effect of the agent and dosing schedule on the patient's quality of life.